RESOURCES
-
-
-
October 30, 2025
Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
Psoriatic arthritis (PsA) is a complex inflammatory disorder that affects up to 30% of psoriasis patients. Its heterogeneous clinical manifestations and lack of standardized diagnostic criteria pose significant challenges for therapy development. Although targeted therapies have advanced in recent years, the unclear pathogenesis and patient variability highlight the need for robust preclinical models. To address this, we established two inducible PsA mouse models designed to support drug efficacy testing and accelerate therapeutic innovation.
-
-
-
-
October 30, 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Clinical Sex Correlates
Complement component C3 is central to the alternative pathway (AP) and plays a key role in the pathogenesis of C3 glomerulopathy (C3G), a rare renal disease characterized by complement dysregulation. To model human-specific complement activity, we developed two humanized C3 mouse models: B6-hC3 (expressing a human C3 transgene) and B6-hC3 mC3 KO (expressing a human C3 transgene with knockout of mouse C3). These models were designed to promote unregulated C3 activation of the alternative pathway (AP) and reproduce C3G-like phenotypes. Through longitudinal phenotyping and RNA sequencing, we sought to elucidate molecular mechanisms underlying disease development and investigate sex-associated gene expression signatures.
-
-
-
-
October 30, 2025
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-Target Humanized Mice
CD20, a well-characterized B-cell surface marker, is central to B-cell activation and differentiation. In addition, it contributes to the pathogenesis of B-cell-mediated diseases, including lymphomas, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Due to its selective expression on B cells, CD20 is an attractive target for therapeutic antibodies. Previously, we established an SLE model in transgenic mouse strains overexpressing human BAFF on a C57BL/6 mouse background (B6-hBAFF, T036794). To extend this platform for CD20-targeted drug evaluation, we generated a dual-humanized model by crossing B6-hBAFF with CD20 humanized mice (BALB/c-hCD20, T057498), resulting in the BAFF/CD20 dual-humanized mice (T065937).
-
-
-
-
June 23, 2025
Semaglutide and Lisinopril Exerts Therapeutic Benefits in a Genetically Engineered Diabetic Nephropathy Mouse Model
Diabetic nephropathy (DN) is a major driver of chronic kidney disease, yet preclinical models often fail to replicate human disease severity. GemPharmatech addresses this by developing an improved translational DN mouse model that mimics progressive human kidney damage—enabling better evaluation of future therapies.
-
-
-
-
June 23, 2025
A Persistent Hypertension Model Developed on the AGT Humanized Mice
Hypertension, a major metabolic syndrome condition, has experienced a rapid increase in global prevalence. AGT (angiotensinogen), the key precursor in the RAAS pathway, serves as a prime target for RNAi therapies. GemPharmatech has developed an AGT humanized mouse model to advance hypertension research and developed a modified human RENIN virus to induce sustained high blood pressure in these mice.
-
-
-
-
June 18, 2025
Development of Preclinical Models for the Evaluation of Conventional and in vivo CAR-T Therapies
Traditional CAR-T therapies require expensive, complex ex vivo T-cell engineering. While in vivo CAR-T generation using lentiviral vectors offers a faster, cheaper alternative, preclinical testing is limited by graft-versus-host disease (GVHD) in immunodeficient mouse models. To overcome this, GemPharmatech developed the NCG-MHC-dKO mouse, featuring dual MHC I/II knockout to minimize GVHD while maintaining human immune cell engraftment. Testing an anti-CD19 CAR lentiviral vector in this model demonstrated successful in vivo CAR-T generation and potent tumor suppression, with no significant GVHD. The NCG-MHC-dKO model enables reliable, long-term evaluation of in vivo CAR-T therapies, enhancing translational research.
-
-
-
-
June 18, 2025
NCG-X: A Novel Mouse Model For Preclinical Studies Evaluating Humanized Erythroid Reconstitution
Hematopoietic stem cell (HSC) transplantation is critical for treating blood cancers and autoimmune diseases, but existing animal models rely on toxic preconditioning (irradiation/chemotherapy), leading to off-target effects that undermine research validity. To overcome this, we developed the NCG-X mouse by introducing a C-KIT (Val831Met) mutation into the NCG mouse. This model enables human HSC engraftment without irradiation or chemoablation, offering a promising platform for immune and erythroid reconstitution studies.
-
-
-
-
June 16, 2025
Applications for SLE patient-derived PBMC-induced mouse model in preclinical pharmacological studies
To advance Systemic lupus erythematosus (SLE) research, GemPharmatech has developed a humanized SLE mouse model by transferring PBMCs from SLE patients into immunodeficient mice (NCG mice). This model replicates key disease features, including high levels of human auto-antibodies and renal immune complex deposition. Furthermore, this model responds to B-cell targeted therapeutic antibodies, demonstrating its utility in evaluating novel therapeutic modalities.
-
-
-
-
May 18, 2025
Repurposing Oncology Drugs to Treat Autoimmune Diseases
Developing new drugs requires a significant investment of time and economic costs. Drug repurposing therefore has significant advantages over developing new drugs. Humanized SLE models exhibit similar pathological features to those seen in patients with SLE, such as high levels of auto-antibodies and pathogenic B cells, and respond positively to treatment with potentially repurposed oncology therapeutics. As such, these models are valuable for the evaluation of other future repurposed B cell-directed oncology drugs.
-